Financials
Financial year 2026
Heran HealthTech Fund I from Antwerpen, company number BE0747662241, closed financial year 2026 with a result of € 2.6 million after tax. For that financial year Heran HealthTech Fund I recorded a gross margin of € -1 million and equity of € 28.5 million. Compared with financial year 2025, the result moved from € -8.8 million to € 2.6 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.
€ 28.5 million
▲ 5% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2.6 million
▲ still € 8.8 million loss in 2025
Profit after tax over the fiscal year.
€ 374,906
▼ 85% vs 2025
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2026. Retained profit grew to € 577,219.
People and assets in 2026
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2026
None
No bank loans on the last day of the fiscal year.
€ 255,166
▼ 26% vs 2025
Supplier invoices still open on the last day of the fiscal year.
€ 1,273
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | - | - | - | € -1,006,200 | |
| Profit after taxes | € 16,041,454 | € -1,578,942 | € -8,813,714 | € 2,558,575 | ▲ € 11.4 million |
| Equity | € 25,122,111 | € 27,319,724 | € 27,192,088 | € 28,542,165 | ▲ 5% |
| Total debts | € 424,389 | € 282,219 | € 388,295 | € 259,289 | ▼ 33% |
| Cash | € 5,412,617 | € 1,391,482 | € 2,432,946 | € 374,906 | ▼ 85% |
| Retained profit | € 9,166,610 | € 7,587,668 | € -1,981,356 | € 577,219 | ▲ € 2.6 million |
| Dividend | € 16,628,762 | € 0 | € 755,311 | € 0 | ▼ 100% |
| Balance sheet total | € 25,546,500 | € 27,601,943 | € 27,580,382 | € 28,801,454 | ▲ 4% |
Key figures of Heran HealthTech Fund I, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to Heran HealthTech Fund I?
What happened at Heran HealthTech Fund I in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: profit of € 2.6 million. Source: NBB ↗
- New establishment in Antwerpen. KBO
- Heran Partners BV became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 16 million profit in 2023 to € 2.6 million profit in 2026.
Best year ever: 2023, with € 16 million profit.
Paid out € 17.4 million in dividends to the owners in total.
A new publication or filing at Heran HealthTech Fund I? We notify you, reason included.
Follow Heran HealthTech Fund IDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Heran Partners comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Heran HealthTech Fund IBehind Heran HealthTech Fund I is Heran Partners BV. The shares are held by Heran Partners (0%). It owns 38.4% of ImmuneSpec, 37.5% of AMARON, 30.6% of FOx Biosystems (in faillissement), 30.3% of ASPECT ANALYTICS, 25.5% of Lynxcare Clinical Informatics and 24% of ONTOFORCE itself.
Directors
According to the 2026 annual accounts
Manager · represented by Katleen Vandersmissen
Also active at: Lynxcare Clinical Informatics, FOx Biosystems, ASPECT ANALYTICS, nuclivision, ImmuneSpec, AMARON, icometrix, ONTOFORCE
since 2020
Shareholders
Participations
38.4%
37.5%
30.3%
24%
Thirona
16.9%
15.1%
Gynaia Inc.
13%
HyperVision Surgical
12.1%
Establishments
Establishment units
Physical locations of this company
Amerikalei 64 box 5
2000 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0747.662.241
- VAT number
- BE 0747.662.241
- Registered office
- Amerikalei 64 bus 5, 2000 Antwerpen
- Names & denominations
- Heran HealthTech Fund I
- Enterprise type
- Rechtspersoon
- Legal form
- Limited partnership
- Legal situation
- Normale toestand
- Start date
- 27 May 2020
- Peppol
- Active · Active since 7 Oct 2025
- Contact
- heranpartners.com [email protected]
- Activities · NACE
Activiteiten van holdings
Holdings